Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06539169 · ClinicalTrials.gov registry record
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
A clinical trial of Cystic Fibrosis and Amyotrophic Lateral Sclerosis, sponsored by xCures.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT06539169: Recruiting study of Cystic Fibrosis and Amyotrophic Lateral Sclerosis, sponsored by xCures.
NCT06539169 is a study of Cystic Fibrosis and Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by xCures. The registered enrollment target is 1,000 participants, above the 173-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (478% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06539169, a study of Cystic Fibrosis and Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by xCures.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in the study by electronic consent (eConsent) and sign a medical records release to permit data collection. Medical records are accessed from institutions directly via eFax or paper fax, online from patient electronic medical record (EMR) portals, direct from DNA/RNA sequencing and molecular profiling vendors, and via electronic health information exchanges. Patients and their treating physicians may also optionally provide medical records. Medical records are received in or converted to electronic/digitized formats (CCDA, FHIR, PDF), sorted by medical record type (clinic visit, in-patient hospital, out-patient clinic, infusion and out-patient pharmacies, etc.) and made machine-readable to support data annotation, full text searches, and natural language processing (NLP) algorithms to further facilitate feature identification.
Conditions Studied
Study Locations (1)
California
- xCures - Los Altos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2026-06-10 |
What NCT06539169 shows while recruiting
NCT06539169 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 173-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (478% higher).
The record links to 10 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT06539169 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06539169 about?
NCT06539169 is a clinical study titled "FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases". FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in the study by electronic consent (eConsent) and sign a medical records release to permit data collection. Medical records a...
What is the current status of trial NCT06539169?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-06-10. Estimated completion is 2026-06-10.
What conditions does trial NCT06539169 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Huntington Disease, Amyloidosis.
Who is sponsoring clinical trial NCT06539169?
This trial is sponsored by xCures, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06539169 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06539169's enrollment target sits among peer trials
1,000 3rd of 169 higher than 167 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI